Differential role of RB in response to UV and IR damage

Por Bosco, Emily E., Knudsen, Erik S.
Publicado em 2005

Tailoring to RB: tumour suppressor status and therapeutic response

Por Knudsen, Erik S., Knudsen, Karen E.
Publicado em 2008

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Por Witkiewicz, Agnieszka K, Knudsen, Erik S
Publicado em 2014

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

Por Knudsen, Erik S., Witkiewicz, Agnieszka K.
Publicado no Oncotarget (2016)

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies

Por Knudsen, Erik S., Witkiewicz, Agnieszka K.
Publicado no Trends Cancer (2017)

The transcriptome of CDK4/6 inhibition

Por Knudsen, Erik S., Witkiewicz, Agnieszka K.
Publicado no Aging (Albany NY) (2017)

Targeting the RB-Pathway in Cancer Therapy

Por Knudsen, Erik S., Wang, Jean Y. J.
Publicado em 2010

The Changing Landscape of Hepatocellular Carcinoma: Etiology, Genetics, and Therapy

Por Knudsen, Erik S., Gopal, Purva, Singal, Amit G.
Publicado em 2014

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

Por Witkiewicz, Agnieszka K., Cox, Derek, Knudsen, Erik S.
Publicado em 2014

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Por Franco, Jorge, Witkiewicz, Agnieszka K., Knudsen, Erik S.
Publicado em 2014

The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy

Por Hutcheson, Jack, Witkiewicz, Agnieszka K, Knudsen, Erik S
Publicado no Cell Cycle (2015)

Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers

Por Witkiewicz, Agnieszka K., Balaji, Uthra, Knudsen, Erik S.
Publicado no Clin Cancer Res (2014)

Dynamic targeting of the replication machinery to sites of DNA damage

Por Solomon, David A., Cardoso, M. Cristina, Knudsen, Erik S.
Publicado em 2004

RB Activity Alters Checkpoint Response and Chemosensitivity in Lung Cancer Lines

Por Reed, Michael F., Zagorski, William A., Knudsen, Erik S.
Publicado em 2007

Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism

Por Kuwahara, Yasumichi, Charboneau, Aubri, Knudsen, Erik S., Weissman, Bernard E.
Publicado em 2010

RB deletion disrupts coordination between DNA replication licensing and mitotic entry in vivo

Por Bourgo, Ryan J., Ehmer, Ursula, Sage, Julien, Knudsen, Erik S.
Publicado em 2011

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

Por Dean, Jeffry L., McClendon, A. Kathleen, Knudsen, Erik S.
Publicado em 2012

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature

Por Knudsen, Erik S., Hutcheson, Jack, Vail, Paris, Witkiewicz, Agnieszka K.
Publicado no Oncotarget (2017)

The history and future of targeting cyclin-dependent kinases in cancer therapy

Por Asghar, Uzma, Witkiewicz, Agnieszka K., Turner, Nicholas C., Knudsen, Erik S.
Publicado no Nat Rev Drug Discov (2015)

Repression of Ah Receptor and Induction of Transforming Growth Factor-β Genes in DEN-Induced Mouse Liver Tumors

Por Peng, Li, Mayhew, Christopher N., Schnekenburger, Michael, Knudsen, Erik S., Puga, Alvaro
Publicado em 2008